氯酯醒治疗血管性痴呆的有效性和安全性研究  

Safety and efficacy of Meclofenoxate in treatment of patients with vascular dementia

作　　者：付剑亮[1] 孙晓江[1] 赵玉武[1] 黄流清[2] 邵福源[2] 

机构地区：[1]上海交通大学附属第六人民医院神经内科,上海200233 [2]上海第二军医大学附属长征医院神经内科,上海200433

出　　处：《中国现代医学杂志》2007年第13期1615-1616,1621,共3页China Journal of Modern Medicine

摘　　要：目的评价氯酯醒胶囊治疗血管性痴呆的有效性及安全性。方法选择56例血管性痴呆患者,用氯酯醒进行12周的治疗(0.2Tid),治疗前后用简易精神状态量表(MMSE)、临床痴呆量表(CDR)及日常生活自理量表(ADL)评分,判定疗效。结果氯酯醒治疗12周后与治疗前相比,MMSE、CDR及ADL分数分别改善4.69、0.82和4.71分,差异具有显著性意义。在用药初期3例出现血压轻度升高,2例出现头晕、头痛,1例出现胃部不适、恶心,2例出现兴奋或失眠等症状。结论氯酯醒能有效治疗血管性痴呆患者,对患者的认知功能、痴呆程度和日常生活自理能力均有改善,且安全性较好。[Objective] To assess the efficacy and safety of Meclofenoxate in treatment of vascular dementia （VaD）. [Methods] 56 patients with VaD were followed up with self-matched study for 12 weeks in department of Neurology and received MMSE, CDR and ADL test. [Results] The results of self-matched trial showed remarkable improvement in MMSE, CDR and ADL by 4.69, 0.82, 4.71 points respectively （P 〈0.01, 0.05, 0.05） respectively after treatment with Meclofenoxate （0.2 tid） for 12 weeks. Eight of 56 patients showed mild side effects, such as dizziness, headache and nausea. [Conclusions] Meclofenoxate is effective in treating patients with VaD. It can improve cognition and ability of daily life. Meclofenoxate was well tolerated and safe.

关 键 词：血管性痴呆 药物评价 氯酯醒 

分 类 号：R743[医药卫生—神经病学与精神病学]